- The share
- Press releases
- Financial calendar
- Financial reports
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Thank you
Recruitment completed for NOVEL study in the US on STEEN Solution™ and XPS™
In March 2014 the Advisory Panel convened by the FDA voted unanimously, by 10 votes to 0, that the XPS™ System with STEEN Solution™ meets the requirements for HDE (Humanitarian Device Exemption) approval. In August 2014 the company received HDE approval from the FDA for the products XPS™ and STEEN Solution™ for sales on the American market. HDE approval entails certain restrictions, amongst other things that no more than 4,000 patients may be treated per year under HDE approval and that separate ethical approval may be required for treatment. The study that has now been completed will form the basis of the company’s PMA application, which means that if it is approved, there will no longer be any such restrictions.
The NOVEL study is continuing with follow-up of the patients for up to one year. XVIVO Perfusion has an ongoing dialogue with the FDA about the design and the time for submission of the PMA application and will post information when this has been done. The PAS (Post Approval Study) required by the FDA, which is a compulsory safety follow-up after all approvals, will include a total of 126+126 patients that will be followed for 3 years. Sixteen more patients in each group are required to complete enrollment into the PAS.
XPS™ is the only CE-marked and FDA-approved (HDE approval) normothermic lung perfusion integrated system on the market today, that provides the clinician the flexibility to evaluate lungs before transplantation by means of a standardized and simplified procedure. XPS™ is used worldwide with good clinical results. The XPS™ and STEEN Solution™ have already been CE-marked and thus approved for sales on the European market, and are also approved for sales in Canada and Australia.
“We are delighted that the PMA study on XPS™ and STEEN Solution™ in the US has now been completed. This will mean that as soon as recruitment for the PAS study is complete, some of the restrictions that were part of the clinical trial will disappear and more patients will have an option to receive an EVLP lung. This will also mean that the company can focus more in the US on tailoring the technology for customers, building up the market and customer service,” says Magnus Nilsson, CEO of XVIVO Perfusion.
July 6, 2017
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101, firstname.lastname@example.org
Magnus Nilsson, CEO, +46 31 788 2150, email@example.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com
This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on July 6, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.